Ege David S.
Known title: See RemarksCIK: 0001829360
Associated companies
Transaction History
| MCRB | ▼ Sell | Open Market | 1,128 | $948 | 8/16/2024 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 2,969 | — | 8/15/2024 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 2,968 | — | 5/15/2024 | View on chart |
| MCRB | ▼ Sell | Open Market | 1,090 | $1K | 5/15/2024 | View on chart |
| MCRB | ▼ Sell | Open Market | 5,010 | $5K | 2/16/2024 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 11,875 | — | 2/15/2024 | View on chart |
| MCRB | ▼ Sell | Open Market | 4,066 | $5K | 10/30/2023 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 11,361 | $0 | 10/27/2023 | View on chart |
| MCRB | ▼ Sell | Open Market | 7,038 | $37K | 4/28/2023 | View on chart |
| MCRB | ▲ Buy | Grant | 20,000 | $0 | 4/27/2023 | View on chart |
| MCRB | ▼ Sell | Open Market | 5,012 | $40K | 10/31/2022 | View on chart |
| MCRB | ▲ Buy | Grant | 20,000 | $0 | 10/27/2022 | View on chart |
| MCRB | ▲ Buy | Grant | 31,746 | $100K | 7/5/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
MCRB to Present Preclinical Data on SER-428 at IDWeek 2026
Seres Therapeutics announced it will present preclinical data for SER-428, an investigational live biotherapeutic intended to reduce the risk of bloodstream infections in critically ill patients, at the upcoming IDWeek 2026 conference. The data will focus on early-stage results that support the development of the oral liquid LBP. The stock is currently trading near its $7.60 support level with an RSI of 22.8, indicating limited recent price momentum.
MCRB to Present Preclinical Data on SER-428 at IDWeek 2026. Seres Therapeutics announced it will present preclinical data for SER-428, an investigational live biotherapeutic intended to reduce the risk of bloodstream infections in critically ill patients, at the upcoming IDWeek 2026 conference. The data will focus on early-stage results that support the development of the oral liquid LBP. The stock is currently trading near its $7.60 support level with an RSI of 22.8, indicating limited recent price momentum.